Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis.
The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.
Three complementary statistical models applied to data from the phase 2 CALLIPER trial consistently favored vidofludimus calcium over placebo, the company said.
A second poster covering patient-reported outcomes showed that treatment effectiveness numerically favored vidofludimus calcium over placebo at weeks 48 and 120, while side effect burden remained comparable between groups. No worsening of depressive or suicidal thoughts was observed with the drug compared to placebo over 120 weeks.
A third poster on safety and tolerability, based on 467 patients treated for up to 120 weeks, showed the overall incidence of adverse events was comparable between vidofludimus calcium and placebo at 69.4% and 68.5%, respectively. Discontinuation rates were identical at 2.6% in both groups, and no cases met Hy's law criteria for liver injury.
CEO Daniel Vitt called the late-breaking analysis “particularly interesting,” as it introduced a new and potentially more comprehensive way to measure overall disability change by capturing both slowing of progression and improvement of disease.
“Together with supportive safety, tolerability and patient-reported data, these findings further strengthen our confidence in the potential of vidofludimus calcium to address key drivers of MS disease progression,” Vitt added.
Immunic shares added 4.5% on the news.